Overview
Long chain fatty acid oxidation disorders are rare, autosomal recessive genetic disorders characterized by acute crises of energy production and chronic energy deficiency.

Dojolvi is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Coverage Guidelines
Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Dojolvi, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted when ALL of the following criteria are met:
1. Member has a diagnosis of long-chain fatty acid oxidation disorders (LC-FAOD)
2. Prescriber has submitted documentation of results from genetic testing or molecular analysis to confirm diagnosis (ex. CPT I or II, LCHAD, TFP, VLCAD deficiency)
3. Prescriber is a specialist in genetic or metabolic disease or medication is being prescribed in consultation with a specialist.
4. Documentation of a trial with a diet consisting of low-fat, high-carbohydrate, and avoidance of fasting
5. Member’s current caloric intake

Continuation of Therapy
Reauthorization may be granted for patient is experiencing benefit from therapy as evidenced by disease stability or disease improvement.
Limitations
1. Initial approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months.

References

Review History
03/17/2021 – Created and Reviewed at March P&T
05/19/2021 – Updated; Added Specialty Pharmacy Limitation. Effective 06/01/2021.

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.